Bionano Genomics (BNGO) Common Equity (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Common Equity data on file, last reported at $37.5 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 22.26% year-over-year to $37.5 million; the trailing twelve-month figure through Mar 2026 stood at $37.5 million (down 22.26% YoY), and the FY2025 full-year result was $44.4 million, up 25.58% from the prior year.
• Common Equity fell to $37.5 million in Q1 2026, from $44.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $311.2 million in Q1 2022 to a low of $35.4 million in Q4 2024.
• A 5-year average of $133.0 million and a median of $82.8 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity sank 64.24% in 2024 and advanced 25.58% in 2025, its largest moves.
• Tracing BNGO's Common Equity over 5 years: stood at $249.4 million in 2022, then slumped by 61.44% to $96.2 million in 2023, then tumbled by 63.21% to $35.4 million in 2024, then increased by 25.58% to $44.4 million in 2025, then decreased by 15.67% to $37.5 million in 2026.
• Business Quant data shows BNGO's Common Equity at $37.5 million in Q1 2026, $44.4 million in Q4 2025, and $49.8 million in Q3 2025.